Financial & Business News

Medical Properties Trust trades at a significant discount to book value, offering substantial upside as management continues to stabilize operations and re-tenant properties. Recent results show progress: net loss narrowed, book value per share increased, and new lease agreements should boost future cash rent. Risks remain with troubled tenants and high leverage, but management's actions and court-approved loans reduce downside and support recovery.

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE: ANRO) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

BAB is a well-constructed, diversified ETF focused on taxable municipal bonds, prioritizing investment-grade credit and moderate maturities. Despite sound design, BAB's yield (around 4%) is lower than alternatives like USFR, BBN, SGOV, or SHYM, given similar or less risk. The fund's conservative approach limits yield; I believe more selective or active strategies can outperform broad muni index funds like BAB.

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Lockheed Martin Corporation (“Lockheed Martin” or the “Company”) (NYSE: LMT) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Capricor Therapeutics, Inc. Investors of Upcoming Deadline

IQVIA Holdings on Tuesday named insider Michael Fedock as Chief Financial Officer, effective February 28, 2026, succeeding Ron Bruehlman who is set to retire.

Dow Inc. remains a key player in the chemicals sector, benefiting from global demand and operational efficiency. The company's strong balance sheet and disciplined capital allocation support its dividend and long-term growth outlook. Recent cost-cutting initiatives and portfolio optimization enhance Dow's competitiveness and profitability.

CVS' Health Care Benefit arm shines in Q2, driven by government plans, even as ACA exit and utilization pressures weigh.

The Nasdaq-100 Index (NDX) is higher by 87.4% for the three years ending August 28. And the Magnificent Seven stocks are taking on larger percentages of other widely observed benchmarks.